The drug, developed by Canada-based Aralez Pharmaceuticals, is designed to release omeprazole into the body before the aspirin to protect the stomach against ulcers.
Aralez CEO Adrian Adams said patients’ out-of-pocket costs for the drug would be less than $1 a day and the company is “very conscious” of the controversy surrounding price hikes of older drugs, according to the report.
Aralez’s stock rose 9.9 percent to $6 a share in morning trading upon news of the approval. Mr. Adams expects omeprazole to produce sales of about $200 million a year.
More articles on supply chain:
FDA approves Medtronic’s drug-coated balloon to treat in-stent restenosis
Allergan to acquire Vitae Pharmaceuticals for $639M
House panel calls on Mylan CEO to explain EpiPen prices at Sept. 21 hearing
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
